The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.a

Cardiomyopathy (acute, subacute, chronic)

Publications

Hamdan D, Darrouzain F, Bejan-Angoulvant T, Isorni C, Zelek L, Paintaud G, Janin A, Bousquet G

A novel way to manage trastuzumab cardiotoxicity.

Cancer chemotherapy and pharmacology. 2018;81(4):791-796

Minichillo S, Gallelli I, Barbieri E, Cubelli M, Rubino D, Quercia S, Dall'Olio M, Rapezzi C, Zamagni C

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.

BMC cancer. 2017;17(1):722

Vasiliadis I, Kolovou V, Kolovou G

Acute cardiotoxic effects of adjuvant trastuzumab treatment.

Angiology. 2014;65(10):950

Aldiab A

Cardiotoxicity with adjuvant trastuzumab use in breast cancer: A single institution's experience.

Journal of the Saudi Heart Association. 2010;22(3):133-6

Guglin M, Hartlage G, Reynolds C, Chen R, Patel V

Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study.

Journal of cardiac failure. 2009;15(8):651-7

Tu CM, Chu KM, Yang SP, Cheng SM, Wang WB

Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review.

The American journal of emergency medicine. 2009;27(7):903.e1-3